Cristiana Catena

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/18905/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Vitamin D Deficiency Is Associated with Glycometabolic Changes in Nondiabetic Patients with Arterial Hypertension. Nutrients, 2022, 14, 311.	4.1	4
2	The Pivotal Role of Oleuropein in the Anti-Diabetic Action of the Mediterranean Diet: A Concise Review. Pharmaceutics, 2022, 14, 40.	4.5	7
3	Cardiovascular Risk in Patients With Takayasu Arteritis Directly Correlates With Diastolic Dysfunction and Inflammatory Cell Infiltration in the Vessel Wall: A Clinical, ex vivo and in vitro Analysis. Frontiers in Medicine, 2022, 9, .	2.6	4
4	Differences in Regulation of Cortisol Secretion Contribute to Left Ventricular Abnormalities in Patients With Essential Hypertension. Hypertension, 2022, 79, 1435-1444.	2.7	6
5	Elevated Intrarenal Resistive Index Predicted Faster Renal Function Decline and Long-Term Mortality in Non-Proteinuric Chronic Kidney Disease. Journal of Clinical Medicine, 2022, 11, 2995.	2.4	7
6	Echocardiographic Comparison of COVID-19 Patients with or without Prior Biochemical Evidence of Cardiac Injury after Recovery. Journal of the American Society of Echocardiography, 2021, 34, 193-195.	2.8	31
7	Nonalcoholic fatty liver and left ventricular remodelling: now the prospective evidence. Journal of Hypertension, 2021, 39, 864-866.	0.5	1
8	Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study. Medicina (Lithuania), 2021, 57, 1017.	2.0	2
9	Short-term cardiac outcome in survivors of COVID-19: a systematic study after hospital discharge. Clinical Research in Cardiology, 2021, 110, 1063-1072.	3.3	28
10	Interactions between vitamin D levels, cardiovascular risk factors, and atherothrombosis markers in patients with symptomatic peripheral artery disease. Vascular Medicine, 2021, 26, 315-316.	1.5	4
11	Plasma Lipoprotein(a) Levels as Determinants of Arterial Stiffening in Hypertension. Biomedicines, 2021, 9, 1510.	3.2	9
12	Secondary hyperparathyroidism is associated with postpartum blood pressure in preeclamptic women and normal pregnancies. Journal of Hypertension, 2021, 39, 563-572.	0.5	1
13	Prognostic Role of Malnutrition Diagnosed by Bioelectrical Impedance Vector Analysis in Older Adults Hospitalized with COVID-19 Pneumonia: A Prospective Study. Nutrients, 2021, 13, 4085.	4.1	10
14	Arterial stiffening in hypertension: is it just high blood pressure?. Reviews in Cardiovascular Medicine, 2021, 22, 1073.	1.4	3
15	Prognostic scores and early management of septic patients in the emergency department of a secondary hospital: results of a retrospective study. BMC Emergency Medicine, 2021, 21, 152.	1.9	4
16	Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 289-292.	3.6	20
17	Atrial fibrillation and its complications in arterial hypertension: The potential preventive role of ï‰-3 polyunsaturated fatty acids. Critical Reviews in Food Science and Nutrition, 2019, 59, 1937-1948.	10.3	4
18	Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. World Journal of Gastroenterology, 2019, 25, 6094-6106.	3.3	14

#	Article	IF	CITATIONS
19	Benzodiazepines: An Old Class of New Antihypertensive Drugs?. American Journal of Hypertension, 2018, 31, 402-404.	2.0	7
20	Mineralocorticoid Receptor Blockers and Aldosterone to Renin Ratio: A Randomized Controlled Trial and Observational Data. Hormone and Metabolic Research, 2018, 50, 375-382.	1.5	10
21	Pre-Procedural Statin Use Is Associated with Improved Long-Term Survival and Reduced Major Cardiovascular Events in Patients Undergoing Carotid Artery Stenting: A Retrospective Study. Journal of Clinical Medicine, 2018, 7, 286.	2.4	6
22	The Bone-Cardiovascular Axis: Mechanisms and Clinical Relevance. International Journal of Endocrinology, 2018, 2018, 1-2.	1.5	5
23	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 641-649.	2.7	94
24	Low-grade inflammation and tryptophan-kynurenine pathway activation are associated with adverse cardiac remodeling in primary hyperparathyroidism: the EPATH trial. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1034-1042.	2.3	15
25	Elevated Blood Pressure in Children of Cardiovascular Risk Mothers: Could Maternal Folic Acid Be the Link?. American Journal of Hypertension, 2017, 30, 473-475.	2.0	0
26	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes and Endocrinology,the, 2017, 5, 689-699.	11.4	595
27	Plasma parathyroid hormone and cardiovascular disease in treatmentâ€naive patients with primary hyperparathyroidism: The <scp>EPATH</scp> trial. Journal of Clinical Hypertension, 2017, 19, 1173-1180.	2.0	14
28	Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism – The randomized, placebo-controlled EPATH trial. Bone, 2017, 105, 212-217.	2.9	8
29	Microalbuminuria and plasma aldosterone levels in nondiabetic treatment-naÃ ⁻ ve patients with hypertension. Journal of Hypertension, 2017, 35, 2510-2516.	0.5	8
30	The SPARTACUS Trial: Controversies and Unresolved Issues. Hormone and Metabolic Research, 2017, 49, 936-942.	1.5	33
31	Long-Term Renal and Cardiac Outcomes after Stenting in Patients with Resistant Hypertension and Atherosclerotic Renal Artery Stenosis. Kidney and Blood Pressure Research, 2017, 42, 774-783.	2.0	9
32	Salt, Aldosterone, and Parathyroid Hormone: What Is the Relevance for Organ Damage?. International Journal of Endocrinology, 2017, 2017, 1-8.	1.5	10
33	Relationship between bone turnover and left ventricular function in primary hyperparathyroidism: The EPATH trial. PLoS ONE, 2017, 12, e0173799.	2.5	10
34	Decreased fibrinolytic activity is associated with carotid artery stiffening in arterial hypertension. Journal of Research in Medical Sciences, 2017, 22, 57.	0.9	3
35	Association of Post-Saline Load Plasma Aldosterone Levels With Left Ventricular Hypertrophy in Primary Hypertension. American Journal of Hypertension, 2016, 29, 303-310.	2.0	6
36	Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism. Journal of Hypertension, 2016, 34, 1778-1786.	0.5	17

#	Article	IF	CITATIONS
37	Moderate Alcohol Consumption Is Associated With Left Ventricular Diastolic Dysfunction in Nonalcoholic Hypertensive Patients. Hypertension, 2016, 68, 1208-1216.	2.7	25
38	The Rising Burden of Hypertensive Renal Disease in Lowâ€Income Countries: Is it Time to Take Action?. Journal of Clinical Hypertension, 2016, 18, 405-407.	2.0	0
39	Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. Thrombosis and Haemostasis, 2016, 116, 162-171.	3.4	32
40	Intrarenal Vascular Resistance is Associated With a Prothrombotic State in Hypertensive Patients. Kidney and Blood Pressure Research, 2016, 41, 929-936.	2.0	8
41	Dietary Salt Intake Is a Determinant of Cardiac Changes After Treatment of Primary Aldosteronism. Hypertension, 2016, 68, 204-212.	2.7	31
42	Aldosterone-to-Renin Ratio Is Associated With Reduced 24-Hour Heart Rate Variability and QTc Prolongation in Hypertensive Patients. Medicine (United States), 2016, 95, e2794.	1.0	6
43	Plasma Parathyroid Hormone Is Independently Related to Nocturnal Blood Pressure in Hypertensive Patients: The Styrian Hypertension Study. Journal of Clinical Hypertension, 2016, 18, 543-550.	2.0	7
44	The vascular response to vasodilators is related to the membrane content of polyunsaturated fatty acids in hypertensive patients. Journal of Hypertension, 2015, 33, 993-1000.	0.5	9
45	Treatment of Primary Aldosteronism and Organ Protection. International Journal of Endocrinology, 2015, 2015, 1-8.	1.5	25
46	Response to "Plasma Homocysteine Levels and Endothelial Dysfunction in Cerebro- and Cardiovascular Diseases in the Metabolic Syndrome― American Journal of Hypertension, 2015, 28, 1490-1490.	2.0	1
47	Aldosterone and Left Ventricular Remodeling. Hormone and Metabolic Research, 2015, 47, 981-986.	1.5	41
48	Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery?. Hormone and Metabolic Research, 2015, 47, 1000-1006.	1.5	19
49	Elevated Homocysteine Levels Are Associated With the Metabolic Syndrome and Cardiovascular Events in Hypertensive Patients. American Journal of Hypertension, 2015, 28, 943-950.	2.0	74
50	Subclinical carotid artery disease and plasma homocysteine levels in patients with hypertension. Journal of the American Society of Hypertension, 2015, 9, 167-175.	2.3	32
51	Plasma Aldosterone and Left Ventricular Diastolic Function in Treatment-NaÃ ⁻ ve Patients With Hypertension. Hypertension, 2015, 65, 1231-1237.	2.7	31
52	Plasma Lipoprotein(a) Levels and Atherosclerotic Renal Artery Stenosis in Hypertensive Patients. Kidney and Blood Pressure Research, 2015, 40, 166-175.	2.0	10
53	Hypovitaminosis D and Organ Damage In Patients With Arterial Hypertension: A Multicenter Double Blind Randomised Controlled Trial of Cholecalciferol Supplementation (HYPODD). High Blood Pressure and Cardiovascular Prevention, 2015, 22, 135-142.	2.2	4
54	Carotid artery stiffness is related to hyperinsulinemia and insulin-resistance in middle-aged, non-diabetic hypertensive patients. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 968-974.	2.6	12

#	Article	IF	CITATIONS
55	The Metabolic Syndrome and the Membrane Content of Polyunsaturated Fatty Acids in Hypertensive Patients. Metabolic Syndrome and Related Disorders, 2015, 13, 343-351.	1.3	6
56	Adrenalectomy Is Comparable With Medical Treatment for Reduction of Left Ventricular Mass in Primary Aldosteronism: Meta-Analysis of Long-Term Studies. American Journal of Hypertension, 2015, 28, 312-318.	2.0	56
57	Early renal failure as a cardiovascular disease: Focus on lipoprotein(a) and prothrombotic state. World Journal of Nephrology, 2015, 4, 374.	2.0	8
58	Effects of the Consumption of Fish Meals on the Carotid IntimaMedia Thickness in Patients with Hypertension: A Prospective Study. Journal of Atherosclerosis and Thrombosis, 2014, 21, 941-956.	2.0	14
59	Aldosterone and the Heart: Still an Unresolved Issue?. Frontiers in Endocrinology, 2014, 5, 168.	3.5	14
60	Fish Meal Supplementation and Ambulatory Blood Pressure in Patients With Hypertension: Relevance of Baseline Membrane Fatty Acid Composition. American Journal of Hypertension, 2014, 27, 471-481.	2.0	18
61	Relationships of plasma lipoprotein(a) levels with insulin resistance in hypertensive patients. Metabolism: Clinical and Experimental, 2014, 63, 1439-1446.	3.4	15
62	Uricaemia and left ventricular mass in hypertensive patients. European Journal of Clinical Investigation, 2014, 44, 972-981.	3.4	18
63	Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Molecular and Cellular Endocrinology, 2014, 394, 13-20.	3.2	48
64	Salt, Hypertension, and Cardiovascular Disease. Journal of Clinical and Laboratory Investigation Updates, 2014, 2, 46-49.	0.4	2
65	Aldosterone, organ damage and dietary salt. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 922-928.	1.9	25
66	Editorial Comment from <scp>D</scp> r <scp>C</scp> atena, <scp>D</scp> r <scp>C</scp> olussi and <scp>D</scp> r <scp>S</scp> echi to Preoperative masked renal damage in <scp>J</scp> apanese patients with primary aldosteronism: Identification of predictors for chronic kidney disease manifested after adrenalectomy. International Journal of Urology, 2013, 20, 692-693.	1.0	0
67	Association of Aldosterone With Left Ventricular Mass in Hypertension: Interaction With Plasma Fibrinogen Levels. American Journal of Hypertension, 2013, 26, 111-117.	2.0	19
68	Non-Alcoholic Fatty Liver Disease is Not Associated with Vitamin D Deficiency in Essential Hypertension. High Blood Pressure and Cardiovascular Prevention, 2013, 20, 33-37.	2.2	9
69	Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era. European Journal of Endocrinology, 2013, 168, C1-C5.	3.7	15
70	Plasma Glucose Levels and Left Ventricular Diastolic Function in Nondiabetic Hypertensive Patients. American Journal of Hypertension, 2013, 26, 1353-1361.	2.0	21
71	Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. Journal of Hypertension, 2013, 31, 3-15.	0.5	96
72	Association of a prothrombotic state with left-ventricular diastolic dysfunction in hypertension. Journal of Hypertension, 2013, 31, 2077-2084.	0.5	16

#	Article	IF	CITATIONS
73	Aldosterone and the Heart: From Basic Research to Clinical Evidence. Hormone and Metabolic Research, 2012, 44, 181-187.	1.5	54
74	Predictive Factors of Left Ventricular Mass Changes after Treatment of Primary Aldosteronism. Hormone and Metabolic Research, 2012, 44, 188-193.	1.5	32
75	Potassium-Sparing Diuretics in Hypertension. , 2012, , .		0
76	A Prothrombotic State is Associated with Early Arterial Damage in Hypertensive Patients. Journal of Atherosclerosis and Thrombosis, 2012, 19, 471-478.	2.0	17
77	Kidney in primary aldosteronism: A key determinant of treatment outcome. World Journal of Hypertension, 2012, 2, 1.	0.8	2
78	Aldosterone and aldosterone antagonists in cardiac disease: what is known, what is new. American Journal of Cardiovascular Disease, 2012, 2, 50-7.	0.5	12
79	Oxidative Stress Is Activated by Free Fatty Acids in Cultured Human Hepatocytes. Metabolic Syndrome and Related Disorders, 2011, 9, 397-401.	1.3	43
80	Involvement of endothelium-dependent and -independent mechanisms in midazolam-induced vasodilation. Hypertension Research, 2011, 34, 929-934.	2.7	27
81	Cardiovascular and Renal Damage in Primary Aldosteronism: Outcomes After Treatment. American Journal of Hypertension, 2010, 23, 1253-1260.	2.0	98
82	Nonalcoholic Fatty Liver Disease in Primary Aldosteronism: A Pilot Study. American Journal of Hypertension, 2010, 23, 2-5.	2.0	41
83	Hyperaldosteronism and Left Ventricular Hypertrophy. Hypertension, 2010, 56, e26; author reply e27.	2.7	8
84	Mineralocorticoid Antagonists Treatment Versus Surgery in Primary Aldosteronism. Hormone and Metabolic Research, 2010, 42, 440-445.	1.5	56
85	Metabolic Dysfunction in Primary Aldosteronism. Hypertension, 2009, 53, e37; author reply e38.	2.7	3
86	Intrarenal Hemodynamics in Primary Aldosteronism before and after Treatment. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1191-1197.	3.6	118
87	The Dual Role of the Kidney in Primary Aldosteronism: Key Determinant in Rescue From Volume Expansion and Persistence of Hypertension. American Journal of Kidney Diseases, 2009, 54, 594-597.	1.9	11
88	Relationship of Plasma Renin With a Prothrombotic State in Hypertension: Relevance for Organ Damage. American Journal of Hypertension, 2008, 21, 1347-1353.	2.0	61
89	Effects of Antihypertensive Drugs on Alcohol-Induced Functional Responses of Cultured Human Endothelial Cells. Hypertension Research, 2008, 31, 345-351.	2.7	13
90	Cardiovascular Outcomes in Patients With Primary Aldosteronism After Treatment. Archives of Internal Medicine, 2008, 168, 80.	3.8	476

#	Article	IF	CITATIONS
91	Nonalcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients. Journal of Hypertension, 2008, 26, 2191-2197.	0.5	34
92	Relationships of Plasma Renin Levels with Renal Function in Patients with Primary Aldosteronism. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 722-731.	4.5	92
93	Long-Term Cardiac Effects of Adrenalectomy or Mineralocorticoid Antagonists in Patients With Primary Aldosteronism. Hypertension, 2007, 50, 911-918.	2.7	312
94	Insulin Resistance and Hyperinsulinemia Are Related to Plasma Aldosterone Levels in Hypertensive Patients. Diabetes Care, 2007, 30, 2349-2354.	8.6	136
95	Renal cysts and hypokalemia in primary aldosteronism: results of long-term follow-up after treatment. Journal of Hypertension, 2007, 25, 1443-1450.	0.5	30
96	Omega-3 Fatty Acids: from Biochemistry to their Clinical Use in the Prevention of Cardiovascular Disease. Recent Patents on Cardiovascular Drug Discovery, 2007, 2, 13-21.	1.5	35
97	Long-term Renal Outcomes in Patients With Primary Aldosteronism. JAMA - Journal of the American Medical Association, 2006, 295, 2638-45.	7.4	328
98	Insulin Sensitivity in Patients with Primary Aldosteronism: A Follow-Up Study. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3457-3463.	3.6	232
99	Renal Function in Primary Aldosteronism. Hypertension, 2006, 48, e110; author reply e111.	2.7	5
100	New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a). Journal of Hypertension, 2005, 23, 1617-1631.	0.5	50
101	Alcohol-Induced Endothelial Changes Are Associated With Oxidative Stress and Are Rapidly Reversed After Withdrawal. Alcoholism: Clinical and Experimental Research, 2005, 29, 1889-1898.	2.4	41
102	Glucose Metabolism In Early Renal Failure. American Journal of Kidney Diseases, 2005, 46, 367.	1.9	2
103	The Emergent Cardiovascular Risk Factors and Organ Damage in Arterial Hypertension. Current Hypertension Reviews, 2005, 1, 189-200.	0.9	Ο
104	Insulin receptors and renal sodium handling in hypertensive fructose-fed rats. Kidney International, 2003, 64, 2163-2171.	5.2	86
105	Cellular mechanisms of insulin resistance in rats with Fructose-Induced hypertension. American Journal of Hypertension, 2003, 16, 973-978.	2.0	137
106	Serum lipoprotein(a) concentrations and alcohol consumption in hypertension. Journal of Hypertension, 2003, 21, 281-288.	0.5	45
107	Abnormalities of Glucose Metabolism in Patients With Early Renal Failure. Diabetes, 2002, 51, 1226-1232.	0.6	75
108	Lipoprotein (a), haemostatic variables and cardiovascular damage in hypertensive patients. Journal of Hypertension, 2000, 18, 709-716.	0.5	15

#	Article	IF	CITATIONS
109	Increased Fibrinogen Levels and Hemostatic Abnormalities in Patients with Arteriolar Nephrosclerosis: Association with Cardiovascular Events. Thrombosis and Haemostasis, 2000, 84, 565-570.	3.4	35
110	Relationship of Fibrinogen Levels and Hemostatic Abnormalities With Organ Damage in Hypertension. Hypertension, 2000, 36, 978-985.	2.7	77
111	Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance. American Journal of Medicine, 2000, 109, 556-561.	1.5	62
112	Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure. Kidney International, 1999, 56, 1049-1057.	5.2	51
113	Hypertension and Abnormalities of Carbohydrate Metabolism Possible Role of the Sympathetic Nervous System. American Journal of Hypertension, 1997, 10, 678-682.	2.0	13
114	Glucose Metabolism and Insulin Receptor Binding and mRNA Levels in Tissues of Dahl Hypertensive Rats. American Journal of Hypertension, 1997, 10, 1223-1230.	2.0	20
115	Abnormalities of Insulin Receptors in Spontaneously Hypertensive Rats. Hypertension, 1996, 27, 955-961.	2.7	47
116	Omega-3 Polyunsaturated Fatty Acids in Blood Pressure Control and Essential Hypertension. , 0, , .		3